To assess the impact of statin use on overall and time to biochemical failure following primary treatment of localized prostate cancer (PCa). 1581 patients undergoing radical prostatectomy (RP) or radiation therapy (RT) for primary treatment of PCa between July 2007 and January 2020 were evaluated for statin use, demographic/oncologic characteristics, and biochemical outcomes.
A number of observational clinical studies suggest that prior primary tumor treatment favorably influences the course of metastatic prostate cancer (PCa), but its mechanisms of action are still speculative.
We report on the post-radical prostatectomy (RP) outcomes of patients enrolled on three randomized, multicenter, clinical trials of intense neoadjuvant androgen deprivation therapy (ADT) therapy prior RP.
To assess the impact of the Personal Optimism With Exercise Recovery (POWER) program on cancer treatment-related side effects among rural cancer survivors. In this retrospective study of data collected between 2016 and 2019, we assessed change in cardiorespiratory fitness, whole-body muscular endurance, physical function and strength, anthropometrics, fatigue, and quality of life (QoL), after participation […]
The indirect impact of the COVID-19 pandemic on cancer outcomes is of increasing concern. However, the extent to which key treatment modalities have been affected is unclear. We aimed to assess the impact of the pandemic on radiotherapy activity in England.
T1 bladder cancer is characterized by high recurrence and aggressive progression. Muscularis mucosae invasion may be a prognostic factor for progression, but the limitations of conventional transurethral resection of bladder tumors make diagnosis difficult.
Molecular assessments of muscle-invasive bladder cancer (MIBC) have yielded several molecular categorizations associated with basal and luminal subtypes or tumor-associated immune cell status (TAICs).
In metastatic castrate sensitive prostate cancer (mCSPC), combined androgen axis inhibition is a standard of care. Noninvasive biomarkers that guide initial therapy decisions are needed. We hypothesized that CellSearch CTC count, an FDA-cleared assay in metastatic castrate resistant PC (mCRPC), is a relevant biomarker in mCSPC.
Recurrent disease after BCG presents a therapeutic challenge. To aid trial development, the US Food & Drug Administration defined ‘adequate BCG’ therapy and adopted the ‘BCG unresponsive’ disease state.
With the advances in minimally invasive surgery and increased familiarity with robotic-assisted laparoscopic prostatectomy (RALP), there has been a trend towards performing multiple robotic cases per day. An area once dominated by single prostatectomy in a day has now grown exponentially. The limits are constantly being pushed to not only minimize the invasiveness of prostate […]
